Conference Presentations, Posters & Abstracts
—
Recent Pharsight®
Contributions
Current
Archive
2010
June
Carrothers TJ. The Clinical Utility Index, a Method for Balancing Efficacy and Safety
in Drug Development Decision-Making. [invited presentation]. Presented at: Pacific Coast Statisticians and Pharmacometricians Innovation Conference (PaSiPhIC);
June 14-16, 2010; San Luis Obispo, CA.
Chanu P, Agoram B, Bruno R. Mechanistic Models to Simulate Dose Response of IgE Suppression Following Dosing of Anti-IgE Monoclonal Antibodies. [oral presentation]. Presented at: 19th Annual Meeting of the Population Approach Group in Europe (PAGE); June 8-11, 2010; Berlin, Germany.
Ezzet F, Prins K, Boucher M. Modeling Adverse Event rates of Opioids for the Treatment of Osteoarthritis Pain using Literature Data. [poster presentation]. Presented at: 19th Annual Meeting of the Population Approach Group in Europe (PAGE); June 8-11, 2010; Berlin, Germany.
Ezzet F, Ribbing J. Bronchial Allergen Challenge in Asthma: A Model for Inhaled Corticosteroids (ICS) and Montelukast using Literature Summary Data. [poster presentation]. Presented at: 19th Annual Meeting of the Population Approach Group in Europe (PAGE); June 8-11, 2010; Berlin, Germany.
Ezzet F. Analysis of Adverse Events using Literature Data: a Simulation Study. [poster presentation]. Presented at: 19th Annual Meeting of the Population Approach Group in Europe (PAGE); June 8-11, 2010; Berlin, Germany.
Jonsson F, Claret L, Knight R,
Olesnyskyj
M, Jacques C, Rajkumar VS, Bruno R.
A Longitudinal Tumor Growth Inhibition Model Based on Serum M-Protein Levels in Patients With Multiple Myeloma Treated by Dexamethasone. [poster presentation]. Presented at: 19th Annual Meeting of the Population Approach Group in Europe (PAGE); June 8-11, 2010; Berlin, Germany.
Frances N, Claret L, Stark FS, Bruno R, Iliadis A. Influence analysis explores heterogeneity in database before data processing by a parametric population method. [poster presentation]. Presented at: 19th Annual Meeting of the Population Approach Group in Europe (PAGE); June 8-11, 2010; Berlin, Germany.
Marouani H, Claret L, Faivre C, Iliadis A. Nonparametric Approach using Gaussian Kernels Estimates Multivariate Probability Densities in Population Pharmacokinetics. [poster presentation]. Presented at: 19th Annual Meeting of the Population Approach Group in Europe (PAGE); June 8-11, 2010; Berlin, Germany.
Dunlavey MR. Derivation of SAEM C-matrix in Phoenix. [poster presentation]. Presented at: 19th Annual Meeting of the Population Approach Group in Europe (PAGE); June 8-11, 2010; Berlin, Germany.
Leary RH. Quasi-Monte Carlo EM Methods for NLME Analysis. [poster presentation]. Presented at: 19th Annual Meeting of the Population Approach Group in Europe (PAGE); June 8-11, 2010; Berlin, Germany.
May
Beliveau M. Integrating QSARs and PBPK Models. [invited presentation]. To be presented at: 14th International Workshop on Quantitative Structure-Activity Relationships in Envinronmental and Health Sciences, Post Conference Course.
May 28, 2010; Montreal, Quebec, Canada.
Marier JF. Biomarkers and Exposure-Response Modeling: Turning PK/PD Data into Knowledge in Non-Clinical and Clinical Studies. [invited presentation]. Presented at: Discovery to Development Symposium on Preclinical Oncology and Biomarkers. May 11, 2010; Montreal, Quebec.
Poland B, Bruno R, Claret L. Optimizing Oncology Drug Development with Modeling and Simulation. [invited presentation]. Presented at: American Course on Drug Development and Regulatory Sciences (ADCRS), Session 3: Learning and Confrming Trials: Finding and Confirming the Right Dose. May 3-6, 2010; Washington, DC.
Rohatagi S, Carrothers TJ, Song S, Green M, Moore H, Lee J, Heyrman R, Wang A, Salazar DE. A FIXED-DOSE COMBINATION OF OLMESARTAN MEDOXOMIL (OM), AMLODIPINE (AML), AND HYDROCHLOROTHIAZIDE (HCTZ): USE OF MODELING AND SIMULATION TO SUPPORT APPROVAL OF INTERMEDIATE DOSE COMBINATIONS NOT INCLUDED IN THE PIVOTAL PHASE 3 STUDY. [poster presentation]. Presented at: American Society of Hypertension 25th Annual Scientific Meeting and Exposition. May 1-4, 2010; New York, New York.
April
Claret L, Jonsson F, Jacques C. Rajkumar VS, Bruno R. A Drug Independent Tumor Burden Reduction-Survival Model in Patients with Multiple Myeloma to Support Early Clinical Development Decisions. [poster presentation]. Presented at: 6th International Symposium on Measurement and Kinetics of In Vivo Drug Effects; April 21-24, 2010; Noordwijkerhout, The Netherlands.
Chittenden J. Estimating a Time-Variant Pharmacokinetic Parameter as a Random Process. [poster presentation]. Presented at: 6th International Symposium on Measurement and Kinetics of In Vivo Drug Effects; April 21-24, 2010; Noordwijkerhout, The Netherlands.
March
Mouksassi S, Leonard P, Marier JF, Beliveau M . Allometric Scaling To Predict Clearance (CL) of a Recombinant Protein (ENB-0040) in Infants and Adults. [poster presentation]. Presented at: Society of Toxicology 2010 Annual Meeting; March 7-11, 2010; Salt Lake City, Utah.
Jomphe C, Lemire I, Leonard P, Reimer ML, Marier JF, Beliveau M. Comparison of the Toxicokinetic (TK) parameters of a Recombinant Protein (ENB-0040) estimated by Non-Compartmental and Compartmental Population Analysis following multiples doses in rats. [poster presentation]. Presented at: Society of Toxicology 2010 Annual Meeting; March 7-11, 2010; Salt Lake City, Utah.
Bruno R, Claret L. Modeling and Simulation of Clinical Tumor Progression Dynamics: Predicting Phase 3 Survival Outcomes from Tumor Size Measurements in Phase 2. [invited presentation]. Presented at: ASCPT 2010 Annual Meeting; March 17-20, 2010; Atlanta, Georgia.
Pan CP, Marier JF, Mouksassi MS, Breitmeyer JB, Royal MA. POPULATION PHARMACOKINETICS OF INTRAVENOUS ACETAMINOPHEN IN NEONATES, INFANTS, CHILDREN AND ADOLESCENTS. [oral presentation]. Presented at: ASCPT 2010 Annual Meeting; March 17-20, 2010; Atlanta, Georgia.
Gibbs J, Fredrickson J, Barbee T, Correa I, Smith B, Lin SL, Gibbs M . Quantitative Model of the Relationship between DPP-4 inhibition and Response: Meta-analysis of Alogliptin, Saxagliptin, Sitagliptin, and Vildagliptin Efficacy Results. [poster presentation]. Presented at: ASCPT 2010 Annual Meeting; March 17-20, 2010; Atlanta, Georgia.
Monteleone JP, Dykstra KH, Lee B, McGuire BM, Berry S, Diaz G, Rhead W, Syplyviy V, Zupanets I, Gargosky S, Martinez A, Mokhtarani M, Scharschmidt B. GLYCEROL PHENYLBUTRYATE (HPN-100), A NOVEL INVESTIGATIONAL AMMONIA SCAVENGING AGENT, DEMONSTRATED UNIQUE BEHAVIOR BASED ON PHARMACOKINETIC / PHARMACODYNAMIC (PK/PD) MODELING. [poster presentation]. Presented at: SOCIETY FOR INHERITED METABOLIC DISORDERS 2010 Annual Meeting; March 27-31, 2010; Albuquerque, New Mexico.
January
Bruno, R. Pharmacokinetics/pharmacodynamics of monoclonal antibody in Oncology. [invited presentation]. Presented at: 31st Annual EORTC-PAMM Group Meeting: Treatment Individualization of Cancer; January 27-30, 2009; Toulouse, France.
Archive